Curevac to shift focus of covid-19 vaccine development to second-generation mrna technology

- covid-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with gsk - first-generation vaccine candidate, cvncov, to be withdrawn from regulatory review due to potential overlap with approval timelines for a second-generation candidate tÜbingen, germany and boston, ma / accesswire / october 12, 2021 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced the strategic decision to focus its covid-19 vaccine development towards the development of second-generation mrna vaccine candidates in collaboration with gsk and to withdraw its first-generation covid-19 vaccine candidate, cvncov, from the current approval process with the european medicines agency (ema).
CVAC Ratings Summary
CVAC Quant Ranking